Evidence map›Paper›PMID 30225265›Full record

ReviewBioMed research international2018

RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy.

Wioletta Olejarz, Dominika Łacheta, Alicja Głuszko, Ewa Migacz, Wojciech Kukwa, Mirosław J Szczepański, Piotr Tomaszewski, Grażyna Nowicka

Abstract readReview
In one paragraph

Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. RAGE Differentially AlteredFrontiers in physiology · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wioletta OlejarzDepartment of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-3211-0947
Dominika ŁachetaDepartment of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.
Alicja GłuszkoLaboratory of Biochemistry and Clinical Chemistry at the Centre for Preclinical Research, Medical University of Warsaw, 02-097 Warsaw, Poland.
Ewa MigaczDepartment of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, 00-739 Warsaw, Poland.
Wojciech KukwaDepartment of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, 00-739 Warsaw, Poland.
Mirosław J SzczepańskiDepartment of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.
Piotr TomaszewskiDepartment of Biochemistry, Second Faculty of Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Grażyna NowickaDepartment of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs) are the key factors indicating a danger to the organism. They recognize the microbial origin pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). The primary response induced by PAMPs or DAMPs is inflammation. Excessive stimulation of the innate immune system occurs in arterial wall with the participation of effector cells. Persistent adaptive responses can also cause tissue damage and disease. However, inflammation mediated by the molecules innate responses is an important way in which the adaptive immune system protects us from infection. The specific detection of PAMPs and DAMPs by host receptors drives a cascade of signaling that converges at nuclear factor-

Indexed as

AtherosclerosisCytokinesHumansInflammationInterferon Type IReceptor for Advanced Glycation End ProductsSignal TransductionToll-Like ReceptorsCytokinesInterferon Type IReceptor for Advanced Glycation End ProductsToll-Like Receptors

Identifiers

PMID30225265
PMCPMC6129363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.